Navigation Links
NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
Date:6/1/2009

port, the evidence for this claim will become increasingly robust."

Reddy BK et al. conducted a randomized Phase IIb, four-arm, open-label study designed to assess the safety and efficacy of nimotuzumab in combination with radiation therapy (RT) or chemoradiation therapy (CRT) in patients with inoperable (Stage III or IVa) squamous cell carcinoma of the head and neck (SCCHN). Stage III-IV SCCHN patients are reported to account for 50-60% of head and neck cancer patients. A total of 92 patients were enrolled of which 76 were considered evaluable. The addition of nimotuzumab to both the radiation and chemoradiation regimens improved the overall response rate, survival rate at 30 months, median progression-free survival and median overall survival. A combined group analysis of the nimotuzumab arms vs. the non-nimotuzumab arms demonstrated a significant difference in overall survival (p=0.0018) favoring nimotuzumab. The addition of nimotuzumab did not add to the severe toxicities of either regimen, with no Grade 3-4 skin toxicities observed. The results of the study are presented in the table below.

    Summary of Efficacy Parameters - Reddy BK et al study:
    -------------------------------------------------------------------------
    PARAMETER                             GROUP A            GROUP B
                                      ---------------------------------------
                                                  RT+               CRT+
                                        RT   nimotuzumab   CRT   nimotuzumab
    -------------------------------------------------------------------------
    Overall Response Rate
     (ORR = CR + PR) (%)      37       76         70       100
    -------------------------------------------------------------------------
    Survival Rates at 30 Months (%)   21.70    39.10      21.70     69.50*
    -------------------------------------------------------------------------
    Median Pro
'/>"/>
SOURCE  YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 

Related biology technology :

1. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
2. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
3. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
4. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
5. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
6. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
7. NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING
8. NOTICE OF YM BIOSCIENCES CONFERENCE CALL TO DISCUSS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER
9. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
10. YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
11. YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Custom Learning Designs, Inc.(CLD) ... solution using Tin Can API combined with its ... is a leading developer of training content and ... worldwide. , Tin Can API is a ... and trainers more accurately measure the Return on ...
(Date:5/21/2013)... ISTANBUL , May 21, 2013 ...  European Dialysis and Transplant Association) is the biggest congress ... renal replacement therapy. Nearly 10,000 participants are in ... discuss the latest research findings. New pioneering studies have ... al. "SOLUBLE FERRIC PYROPHOSPHATE (SFP) ADMINISTERED VIA HEMODIALYSATE REDUCES ...
(Date:5/21/2013)... New York , May 21, 2013 ... by Transparency Market Research ( http://www.transparencymarketresearch.com ) "Biochip Products ... Research, IVD Tests) - U.S. Industry Analysis, Size, Share, Growth, ... 2.4 billion in 2011 and is expected to grow ... to reach an estimated value of USD 4.7 billion ...
(Date:5/21/2013)... ROCKVILLE, Md. , May 21, 2013 /PRNewswire/ ... "Phase 1 study of margetuximab (MGAH22), an Fc-modified ... solid tumors expressing the HER2 oncoprotein," will be ... American Society of Clinical Oncology during the Developmental ... June 3 at 4:15 – 4:30 PM.  The ...
Breaking Biology Technology:CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... new facility, based in Los Angeles, California is anticipated ... ability to supply its new, generation of ... ANGELES, Oct. 6 Today, Grifols SA (Grifols), a,global ... a new,92,000 square foot, intravenous immune globulin (IVIG) production ...
... ANTWERP and AALST , Belgium, AHMEDABAD, India ... Research, genae associates,Cardiovascular Center Aalst and J.B. ... a Core Laboratories joint venture, called imaeon., ... performance of medical images,analysis for clinical research ...
... deCODE genetics,(Nasdaq: DCGN ) today announced that ... Nasdaq Stock Market stating that for 10 consecutive trading,days ... below $50 million,the minimum level required for continued listing ... Marketplace Rule 4450(b)(1)(A). The notice,further stated that deCODE also ...
Cached Biology Technology:Grifols Breaks Ground on New IVIG Facility 2Core Laboratories Joint Venture Agreement Between genae associates, VIBGYOR Scientific Research, Cardiovascular Center Aalst and J.B. Dahm 2deCODE Receives Nasdaq Deficiency Notice Relating to Market Value 2deCODE Receives Nasdaq Deficiency Notice Relating to Market Value 3
(Date:5/21/2013)... When infections occur in the body, stem cells ... multiplying and differentiating into mature immune cells that ... inflammation can deplete these cell populations, potentially leading ... as cancer. Now, a team of researchers led ... (Caltech) has found that, in mouse models, the ...
(Date:5/21/2013)... phosphatidylserine is a natural food supplement produced from ... and slow memory loss, it,s a popular treatment ... team headed by Prof. Gil Ast and Dr. ... Human Molecular Genetics have discovered that ... involved in degenerative brain disorders, including Parkinson,s disease ...
(Date:5/21/2013)... , Where? Copenhagen, Denmark: Bella Center Congress ... , Why? An annual meeting ... developments, manufacturing and installation, drawing on leading experiences from ... edition from a record of more than 900 abstracts ... plenary and oral presentations, more than 460 visual presentation, ...
Breaking Biology News(10 mins):Keeping stem cells strong 2Common food supplement fights degenerative brain disorders 221st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4
... people in the United States alone suffer from rheumatoid arthritis ... in the joints. Now researchers at Brigham and Women,s Hospital ... for treating these diseases and others. Among its advantages, ... an affected joint, and could dispense that medicine on demand ...
... copepods rule the world, at least when it comes ... organisms in the seas, copepods are an important link ... To understand and predict how copepods respond to environmental ... new copepods are born, but how many are dying, ...
... Lockheed Martin (NYSE: LMT ) has been ... of the Year" by Frost and Sullivan, recognizing the ... high levels of customer value. "Lockheed ... that play an important role our customer,s law enforcement ...
Cached Biology News:Injectable gel could spell relief for arthritis sufferers 2Injectable gel could spell relief for arthritis sufferers 3Death -- not just life -- important link in marine ecosystems 2Lockheed Martin Named Biometrics "Company of the Year" by Frost and Sullivan 2
... FACSVantageTM SE flow cytometry system is the ... For over 25 years, BD cell sorters ... found in leading university, pharmaceutical, and biotechnology ... meet the research demands of today, we ...
Reacti-Bind DNA Coating Solution...
... The versatile ST-195 allows real-time observations ... conditions. This instrument has 64 different strain ... CO2 incubator. The thin silicon strain chamber ... inverted microscopes and fluorescence microscopy. ST-195 can ...
... Control and regulate cell stretching or compression ... microscope stage. Computer controlled so you can ... the strain to produce 64 unique strain ... then the ST-150. Both models are compatible ...
Biology Products: